Pancreatic Neuroendocrine Tumors (pNET) Market was valued at USD 1.85 billion in 2024 and is projected to reach USD 4.35 billion by 2034

Market Overview
The Pancreatic Neuroendocrine Tumors (pNET) Market was valued at USD 1.85 billion in 2024 and is projected to reach USD 4.35 billion by 2034, growing at a strong CAGR of 9.1% during the forecast period.
pNETs are rare malignancies arising from the hormone-producing cells of the pancreas, classified into functioning (hormone-secreting) and non-functioning tumors. While often slow-growing, pNETs can become aggressive and metastasize, requiring targeted therapies, peptide receptor radionuclide therapy (PRRT), surgery, and systemic treatments.

Rising incidence of pancreatic NETs, significant improvements in molecular diagnostics, increasing use of targeted drugs such as everolimus and sunitinib, and growing adoption of PRRT have contributed to strong market growth worldwide.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71609

Market Dynamics
Drivers
• Growing incidence and improved detection of pNETs through advanced imaging (CT, MRI, Ga-68 DOTATATE PET-CT).
• Increased adoption of targeted therapies including everolimus, sunitinib, and additional emerging TKIs.
• Expanding use of PRRT (Lutathera - Lu-177) for somatostatin receptor-positive tumors.
• Rising clinical awareness and multidisciplinary treatment approaches.
• Growth in research targeting angiogenesis, mTOR pathways, and novel biomarkers.

Restraints
• Extremely high treatment costs for PRRT and targeted therapies.
• Limited treatment options for high-grade or poorly differentiated pancreatic NETs.
• Shortage of nuclear medicine facilities in developing markets.
• Treatment-related side effects such as stomatitis, gastrointestinal disturbances, and cytopenias.
• Complex diagnosis requiring specialized imaging and pathology expertise.

Opportunities
• Development of next-gen PRRT combinations improving progression-free survival.
• Increasing research in immunotherapy, including checkpoint inhibitors for aggressive pNETs.
• Growing demand for biomarker-based personalized treatment planning.
• Investment in AI-supported NET imaging and early detection prediction models.
• Rising number of clinical trials exploring multi-targeted kinase inhibitors.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71609/pancreatic-neuroendocrine-tumors-pnet-market

Market Growth Outlook (2024-2034)
The pNET market is expected to rise from USD 1.85 billion in 2024 to USD 4.35 billion by 2034, driven by expanding access to PRRT, rapid adoption of molecular targeted therapies, and a strong pipeline of innovative therapies.
Personalized medicine approaches and integration of advanced diagnostic imaging will further improve outcomes and expand market potential.

Segmentation Analysis
By Tumor Type
• Functioning pNETs: Include insulinomas, gastrinomas, glucagonomas, VIPomas, somatostatinomas; present with hormone-related symptoms.
• Non-Functioning pNETs: More common; often detected incidentally or at later stages.

By Treatment Type
Targeted Therapies:
• Everolimus (mTOR inhibitor) and sunitinib (tyrosine kinase inhibitor) remain standard systemic treatments for progressive pNETs.
• New TKIs and mTOR pathway drugs are under clinical development.
Peptide Receptor Radionuclide Therapy (PRRT):
• Lutathera (Lu-177 DOTATATE) is widely used for somatostatin receptor-positive advanced pNETs.
Somatostatin Analogs (SSAs):
• Octreotide and lanreotide used for symptom management and tumor stabilization.

Chemotherapy:
• Streptozocin-based regimens, temozolomide (TEM), and capecitabine often used in high-grade or aggressive pNETs.
Surgery & Ablative Techniques:
• Curative treatment for early tumors; ablative methods for metastatic disease control.

By Diagnosis
• Biomarker Testing: Chromogranin A, gastrin, insulin, glucagon, VIP levels.
• Advanced Imaging: Ga-68 DOTATATE PET-CT, CT, MRI, SPECT imaging.
• Pathology & Grading: Ki-67 index, mitotic count, and molecular profiling.
• Genetic Testing: MEN1, VHL, TSC, and other syndromic risk assessments.

By End User
• Tertiary Hospitals & Oncology Centers offering multidisciplinary pNET management.
• Nuclear Medicine Facilities providing PRRT therapy.
• Diagnostic Imaging Centers specialized in NET scans.
• Research Institutes focused on translational and clinical oncology research.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71609

Regional Insights
North America
North America leads due to high early-diagnosis rates, broad availability of PRRT, established oncology networks, and widespread adoption of targeted therapies. The U.S. holds the largest market share.

Europe
Europe is a strong market supported by advanced PRRT facilities, robust NET guidelines, and significant investment in molecular oncology research. Germany, France, Italy, and the UK are key regional contributors.

Asia Pacific
Asia Pacific shows the fastest growth, driven by rising cancer incidence, expanding diagnostic capabilities, improving nuclear medicine infrastructure, and rapid adoption of targeted therapies in China, India, Japan, and South Korea.

Latin America & Middle East/Africa
Growth is moderate, restrained by high therapy costs and limited PRRT availability, though adoption is increasing as oncology services improve.

Competitive Landscape
The pNET market includes leaders in targeted therapy development, PRRT manufacturers, and oncology diagnostics firms.

Key Companies Include:
• Novartis (Lutathera, Sandostatin)
• Pfizer
• Ipsen (Somatuline Depot)
• Roche
• AstraZeneca
• Bayer
• Merck
• GE Healthcare (imaging technologies)
• Thermo Fisher Scientific (diagnostic tools)
• Advanced Accelerator Applications (PRRT innovations)

These companies are expanding targeted therapy portfolios, developing novel radionuclide compounds, and advancing biomarker-driven treatment approaches.

Recent Developments
• Increasing global expansion of Lutathera PRRT access for advanced pNET patients.
• New trials studying PRRT combined with everolimus or immunotherapy.
• Development of second-generation somatostatin analogs with longer efficacy duration.
• AI-enhanced detection models for early identification of pancreatic NETs.
• Growing use of molecular profiling to guide personalized therapy selection.

This report is also available in the following languages : Japanese (膵神経内分泌腫瘍(PNET)市場), Korean (췌장 신경내분비 종양(PNET) 시장), Chinese (胰腺神经内分泌肿瘤(PNET)市场), French (Marché des tumeurs neuroendocrines pancréatiques (PNET)), German (Markt für pankreatische neuroendokrine Tumoren (PNET)), and Italian (Mercato dei tumori neuroendocrini pancreatici (PNET)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71609

Our More Reports:

Prediabetes Market
https://exactitudeconsultancy.com/reports/72063/prediabetes-market

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market
https://exactitudeconsultancy.com/reports/72065/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-market

Partial Epilepsy Market
https://exactitudeconsultancy.com/reports/72067/partial-epilepsy-market

Partial Seizure Market
https://exactitudeconsultancy.com/reports/72069/partial-seizure-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.